Metabolism is a process in which human body generates energy from the food humans eat. The food that humans consume comprises proteins, carbohydrates, and fats. Chemicals in human digestive system break the food parts down into sugars and acids. Metabolic disorders occur when abnormal chemical reactions in human body disturb this process. This is due to enzyme deficiency: as all processes in the body are controlled by enzymes. Any disturbance in the pathways involved in the development and metabolism of carbohydrates, proteins, and fats, leads to metabolic disorder.
Increase in academia-industry collaborations for drug developments is the key factor responsible for the growth of metabolic disorder therapeutics market. Furthermore, growing diabetic population is significantly contributing to the growth of this market. Low compliance, adherence rate for metabolic disorder therapies and availability of alternative treatment option are the major challenges faced by the players operating in this market. The global metabolic disorder therapeutics market is anticipated to present several opportunities of growth of market size over the forecast period due to strategic collaborations and acquisition and increased R & D investment.
The report segments the metabolic disorder therapeutics market by types of disease and by region. Market segmentation based on types of disease includes diabetes, obesity, hypercholesterolemia and lysosomal storage disease. Among segments given above, diabetes drug segment was the leading segment and accounted for highest market share over 64% globally in 2015. The increasing diabetic population across the globe is one of the significant factors propelling the growth of this segment.
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, and Rest of the World (RoW). North America was the largest market for metabolic disorder and likely to continue its dominance with a majority market shares globally over the period of 2014 to 2015. The US was the major contributor in the region, as half of the adult population in the country is suffering from diabetes over past couple of years. Following North America, Asia Pacific accounted to be the most prominent region for metabolic disorder over the forecast period. Healthcare reforms across the region and rising diabetic population especially in India are anticipated to boost the growth in the Asia - Pacific market.
The companies covered in the report include:
- Novo Nordisk
- Eli Lily
- Actelion Pharmaceuticals
- Amicus Therapeutics
- Arena Pharmaceuticals
- Astellas Pharma
- Boehringer Ingelheim
- CKD Bio
- Concord Biotech
- CymaBay Therapeutics
- Daiichi Sankyo
- Dance Biopharm
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of metabolic disorders therapeutics globally as well as regionally. Moreover, the Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.
The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of metabolic disorders therapeutics market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2022. We also have highlighted future trends in the metabolic disorders therapeutics market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.
This report will help manufacturers, suppliers and distributors of the metabolic disorders therapeutics market to understand the present and future trends in this market and formulate their strategies accordingly.
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Metabolic Disorders Therapeutics Market Overview
3.2 Market Dynamics
3.7 Porter’s Five Forces Analysis
3.8 Growth Matrix Analysis
3.9 Competitive Landscape in the Metabolic Disorders Therapeutics Market
4. Global Metabolic Disorders Therapeutics Market, by Disease Type, (USD Million) 2014-2022
4.5 Lysosomal storage disease
5. Global Metabolic Disorders Therapeutics Market, by Region, (USD Million) 2014-2022
5.2 North America
5.2.1 North America Metabolic Disorders Therapeutics Market, by drug type (USD Million)
5.2.2 North America Metabolic Disorders Therapeutics Market by country (USD million)
5.3.1 Europe Metabolic Disorders Therapeutics Market, by drug type (USD Million)
5.3.2 Europe Metabolic Disorders Therapeutics Market by country (USD million)
5.4 Asia Pacific
5.4.1 Asia- Pacific Metabolic Disorders Therapeutics Market, by drug type (USD Million)
5.4.2 Asia- Pacific Metabolic Disorders Therapeutics Market, by country (USD Million)
5.5.1 RoWMetabolic Disorders Therapeutics Market, by drug type (USD Million)
6. company Profiles
6.1 Astazeneca Plc
6.2 Novo Nordisk
6.5 Eli Lily
6.7 Actelion Pharmaceuticals
6.8 Amicus Therapeutics
6.9 Arena Pharmaceuticals,
6.12 CKD Bio